In this video from Boehringer Ingelheim Idiopathic Pulmonary Fibrosis shared in September 2014, Professor Vincent Cottin from the National Reference Center for Rare Pulmonary Diseases in Lyon, France talks about how difficult it is to diagnose idiopathic pulmonary fibrosis and how often it’s misdiagnosed. Find out more…
Typically speaking, I pride myself on consciously choosing not to express hatred toward anyone or anything. It is my personal belief that the word hate is overused in our society, and that it can have terribly negative effects on people overall, impacting the general mood, creating a toxic work place,…
The University of Alabama at Birmingham’s cystic fibrosis (CF) research center has chosen a Dutch company’s advanced X-ray CAT-scan system to help it conduct animal research in CF, pulmonary fibrosis (PF), chronic obstructive pulmonary disease (COPD), and sinonasal conditions. Utrecht-based MILabs’  U-CTUHR microCT system will provide researchers at the University…
In this short video from Boehringer Ingelheim Idiopathic Pulmonary Fibrosis shared in September 2014, Professor Vincent Cottin from the Université Claude Bernard Lyon, France, talks about diseases which can often be confused with idiopathic pulmonary fibrosis. Find out about the importance of early diagnosis of pulmonary fibrosis. …
Treating idiopathic pulmonary fibrosis (IPF) patients with the anti-IPF drug Esbriet (pirfenidone) before and after lung surgery could be protective against acute exacerbation, or worsening of IPF, a life-threatening complication associated with lung-cancer surgery.
In this short video from Boehringer Ingelheim Idiopathic Pulmonary Fibrosis shared in September 2015, Dr. Toby Maher from the Royal Brompton Hospital in London, UK, talks about ways pulmonary fibrosis patients can adapt their lifestyle to improve their quality of life. Find out what some pulmonary fibrosis patients…
Global Blood Therapeutics has enrolled its first patient in the ZEPHYR Phase 2a clinical study assessing the safety and effectiveness of GBT440 in treating hypoxemia (low levels of oxygen in the blood) in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest. GBT440 is an…
In this short video from Boehringer Ingelheim Idiopathic Pulmonary Fibrosis shared in September 2014, Professor Vincent Cottin from the National Reference Center for Rare Pulmonary Diseases in Lyon, France talks about how excessive coughing impacts the lives of patients with idiopathic pulmonary fibrosis (IPF). Discover six risk factors…
Blocking a particular pathway — called c-Jun N-terminal Kinase (JNK) — may reduce lung remodeling and fibrosis, researchers said in a multi-part study reporting the effects of a JNK inhibitor in a mouse model and, subsequently, in a clinical trial involving patients with idiopathic pulmonary fibrosis (IPF). The study, “JNK inhibition reduces lung…
Yesterday, Kim Fredrickson joined Pulmonary Fibrosis News and hosted a special Facebook Live about being a good friend to yourself while living with pulmonary fibrosis (PF). Read Kim’s full column about it here. “There are so many things we can’t control when you have PF,…
Get regular updates to your inbox.
